Aug 4, 2026 08:01AM
Aug 4, 2026 08:00AM
Apr 7, 2026 08:00AM
Mar 26, 2026 08:02AM
Mar 26, 2026 08:00AM
Mar 16, 2026 08:02AM
Mar 16, 2026 08:00AM Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
Nov 19, 2025 08:01AM
Nov 19, 2025 08:00AM
Jul 28, 2025 08:00AM
Jul 23, 2025 08:00AM
Jun 16, 2025 08:00AM
May 29, 2025 08:04AM
May 29, 2025 08:00AM Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
May 19, 2025 08:03AM
May 19, 2025 08:00AM
May 13, 2025 08:00AM
May 8, 2025 08:01AM
May 8, 2025 08:00AM
May 7, 2025 08:00AM
Mar 25, 2025 08:00AM Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
Mar 18, 2025 08:00AM
Mar 11, 2025 08:00AM
Mar 4, 2025 08:11AM
Mar 4, 2025 08:10AM
Feb 25, 2025 08:00AM
Feb 19, 2025 08:04AM
Feb 19, 2025 08:00AM Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
Jan 15, 2025 08:00AM
Dec 18, 2024 08:00AM
Dec 12, 2024 08:00AM
Nov 19, 2024 08:02AM
Nov 19, 2024 08:00AM
Oct 16, 2024 08:06AM
Oct 16, 2024 08:00AM Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Oct 15, 2024 08:04AM
Oct 15, 2024 08:00AM
Oct 10, 2024 08:00AM
Aug 26, 2024 08:04AM
Aug 26, 2024 08:00AM
Aug 19, 2024 08:06AM
Aug 19, 2024 08:00AM Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stres
Aug 12, 2024 08:03AM
Aug 12, 2024 08:00AM
Aug 6, 2024 08:00AM
Aug 5, 2024 09:10AM
Aug 5, 2024 09:09AM
Jul 31, 2024 08:00AM
Jul 31, 2024 08:00AM Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
Jul 12, 2024 08:00AM

1,216,208 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All